纳米技术即时检测设备在糖尿病肾病中的应用
本研究验证了一种基于纳米技术的多分析物即时检测设备,用于检测糖尿病及糖尿病肾病相关标志物。研究分两阶段:概念验证和临床验证,共筛查4717人,第二阶段在529名受试者中测试。结果显示该设备与实验室检测结果具有极好相关性,有望用于资源匮乏地区的早期筛查。
要点
- 纳米技术即时检测设备可定量测量HbA1c、血红蛋白、血清白蛋白、微量白蛋白尿和尿白蛋白肌酐比。
- 设备无需专业培训人员,操作微创,结果在1分钟内提供。
- 该设备与实验室金标准结果相关性极好,适用于早期糖尿病肾病筛查。
核心结论
- 基于纳米技术的即时检测设备可定量测量HbA1c、血红蛋白、血清白蛋白、微量白蛋白尿和尿白蛋白肌酐比,用于早期糖尿病肾病检测。
- 该设备与实验室结果显示出极好的相关性,有望用于资源匮乏地区的早期筛查。
研究设计与样本
- 前瞻性研究分两阶段:第一阶段为概念验证,随机样本用即时检测设备测试并与实验室金标准对比;第二阶段在特征明确的患者队列中进行临床验证。
- 研究共筛查4717人(第一阶段2576人,第二阶段2141人);第二阶段在529名受试者中测试样本,包括120例1型糖尿病、255例2型糖尿病、54例无糖尿病、400例慢性肾脏病2期和30例慢性肾脏病3期患者。
主要发现
- 即时检测设备与实验室金标准结果之间显示出极好的相关性。
- 设备可在1分钟内提供结果,操作微创且无需专业培训人员。
临床怎么用
- 该设备可用于糖尿病和糖尿病肾病的早期检测,尤其适用于糖尿病患病率快速增长的偏远社区和资源匮乏地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Early detection of diabetes mellitus (DM) and diabetic kidney disease (DKD) is important for preventing end-stage renal failure and reducing cardiovascular complications. Availability of a validated point-of-care (PoC) device that can measure various DKD markers would be useful in this respect, especially in resource-poor parts of the world. METHODS: We validated a novel nanotechnology-based multianalyte PoC device (minimally invasive and does not require trained medical personnel) against laboratory gold standard tests for the detection of 5 biomarkers related to management of DM and DKD. The prospective study was funded by an International Society of Nephrology American Nephrologists of Indian Origin grant in 2 phases: (i) proof of concept: random samples were tested for the analytes with the PoC device and correlated with the laboratory gold standard; and (ii) clinical validation in a well-characterized cohort of patients. A nonenzymatic- and nonantibody-based electrochemical PoC device for quantitative measurement of markers-glycosylated hemoglobin (HbA1c), hemoglobin, serum albumin, microalbuminuria, urine creatinine, and albumin-to-creatinine ratio-was developed and used in this study. The disposable strips were interfaced with a multipotentiostat hand-held PoC device (3.7-V rechargeable lithium battery, 5-inch touch screen, Bluetooth enabled) working in amperometry mode, which provided the results in <1 minute. Data were analyzed using linearity plots and Bland-Altman difference plot analysis. RESULTS: A total of 4717 individuals were screened during the study (phase 1: 2576 and phase 2: 2141.) In phase 2, samples were tested in 529 subjects (346 females)-120 subjects with type 1 DM, 255 subjects with type 2 DM, 54 subjects without DM, 400 subjects with stage 2 chronic kidney disease, and 30 subjects with stage 3 chronic kidney disease. CONCLUSION: A nanotechnology-based PoC device for quantitative measurement of HbA1c, hemoglobin, serum albumin, microalbuminuria, and the urine albumin-to-creatinine ratio was developed for detection of early DKD and showed excellent correlation between the device and laboratory results. This device has the potential for early detection of DM and/or DKD, especially in remote communities in underserved areas of the world where prevalence of diabetes is rapidly increasing.
引用
- Kumar V, Hebbar S, Bhat A, et al. Application of a Nanotechnology-Based, Point-of-Care Diagnostic Device in Diabetic Kidney Disease. Kidney Int Rep. 2018. PMID: 30197977. doi:10.1016/j.ekir.2018.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。